1. Heidenreich PA, Albert NM, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circulation: Heart Failure. 2013 May;6(3):606-19.
2. Page RL, O’Bryant CL, et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation. 2016 Aug 9;134(6):e32-69
3. Holt A, Strange JE, Nouhravesh N, et al. Heart Failure Following Anti-Inflammatory Medications in Patients With Type 2 Diabetes Mellitus. J Am Coll Cardiol. 2023 Apr 18;81(15):1459-1470. doi: 10.1016/j.jacc.2023.02.027.
4. Arfè A, Scotti L, Varas-Lorenzo C, et al; Safety of Non-steroidal Anti-inflammatory Drugs (SOS) Project Consortium. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016 Sep 28;354:i4857. doi: 10.1136/bmj.i4857.
5. Gislason GH, Rasmussen JN, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Archives of internal medicine. 2009 Jan 26;169(2):141-9
6. Writing Committee Members; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Card Fail. 2022 May;28(5):e1-e167. doi: 10.1016/j.cardfail.2022.02.010.
7. Sheikh IM, Hassan OA, Adam SM, et al. Association of Pioglitazone With Major Adverse Cardiovascular Events, All-Cause Mortality, and Heart Failure Hospitalizations: A Systematic Review. Cureus. 2023 Oct 12;15(10):e46911. doi: 10.7759/cureus.46911.
8. American Diabetes Association. Standards of medical care in diabetes—2016: summary of revisions. Diabetes care. 2016 Jan 1;39(Supplement 1):S4-5
9. Deacon CF, Holst JJ. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert opinion on pharmacotherapy. 2013 Oct 1;14(15):2047-58.
10. Monami M, Dicembrini I, et al. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutrition, Metabolism and Cardiovascular Diseases. 2014 Jul 1;24(7):689-97.
11. Misbin RI, Green L, et al. Lactic acidosis in patients with diabetes treated with metformin. New England Journal of Medicine. 1998 Jan 22;338(4):265-6.
12. Eurich DT, McAlister FA, et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. Bmj. 2007 Sep 6;335(7618):497
13. US Food and Drug Administration. FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. 2016. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM494140.pdf
14. Davis BR, Cutler JA, et al. Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial. Annals of internal medicine. 2002 Sep 3;137(5_Part_1):313-20.
15. Sica DA. Doxazosin and congestive heart failure. Congestive Heart Failure. 2002 May;8(3):178-84
16. Zhang Y, Cheng Z. Sympathetic inhibition with clonidine prolongs survival in experimental chronic heart failure. International journal of cardiology. 2000 Apr 28;73(2):157-62
17. Walsh RA. The effects of calcium-entry blockade on left ventricular systolic and diastolic function. Circulation. 1987 Jun;75(6 Pt 2):V43-55
18. Vider E, Zada I. The Use of Calcium Channel Blockers in Heart Failure. The Journal for Nurse Practitioners. 2018;15(1):149-150
19. Nix, DE. Cardiotoxicity induced by antifungal drugs. Current Fungal Infection Reports. 2014;8(2):129-138
20. Rogers KC, Oliphant CS, et al. Clinical efficacy and safety of cilostazol: a critical review of the literature. Drugs. 2015 Mar 1;75(4):377-95